<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epidemiologic studies have correlated elevated plasma fibrinogen (<z:hpo ids='HP_0011899'>hyperfibrinogenemia</z:hpo>) with risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> and arterial and <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, it is unknown whether <z:hpo ids='HP_0011899'>hyperfibrinogenemia</z:hpo> is merely a biomarker of the proinflammatory disease state or is a causative mechanism in the etiology </plain></SENT>
<SENT sid="2" pm="."><plain>We raised plasma fibrinogen levels in mice via intravenous infusion and induced <z:mp ids='MP_0005048'>thrombosis</z:mp> by <z:chebi fb="2" ids="30808">ferric chloride</z:chebi> application to the carotid artery (high shear) or saphenous vein (lower shear); <z:hpo ids='HP_0011899'>hyperfibrinogenemia</z:hpo> significantly shortened the time to occlusion in both models </plain></SENT>
<SENT sid="3" pm="."><plain>Using immunohistochemistry, turbidity, confocal microscopy, and elastometry of clots produced in cell and tissue factor-initiated models of <z:mp ids='MP_0005048'>thrombosis</z:mp>, we show that <z:hpo ids='HP_0011899'>hyperfibrinogenemia</z:hpo> increased <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> fibrin content, promoted faster fibrin formation, and increased fibrin network density, strength, and stability </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0011899'>Hyperfibrinogenemia</z:hpo> also increased <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> resistance to tenecteplase-induced thrombolysis in vivo </plain></SENT>
<SENT sid="5" pm="."><plain>These data indicate that <z:hpo ids='HP_0011899'>hyperfibrinogenemia</z:hpo> directly promotes <z:mp ids='MP_0005048'>thrombosis</z:mp> and thrombolysis resistance and does so via enhanced fibrin formation and stability </plain></SENT>
<SENT sid="6" pm="."><plain>These findings strongly suggest a causative role for <z:hpo ids='HP_0011899'>hyperfibrinogenemia</z:hpo> in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mp ids='MP_0005048'>thrombosis</z:mp> and have significant implications for thrombolytic therapy </plain></SENT>
<SENT sid="7" pm="."><plain>Plasma fibrinogen levels may be used to identify patients at risk for <z:mp ids='MP_0005048'>thrombosis</z:mp> and inform thrombolytic administration for treating <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mp ids='MP_0005048'>thrombosis</z:mp>/<z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
</text></document>